Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503525-19-00

Acronym

NG-641-03

Enrollment

Registered

2023-05-23

Start date

Unknown

Completion date

2023-12-13

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epithelial tumours, Metastatic cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026